preventive-medicine
(2)
Brian Finrow’s Second Draft of Biotech Starts With Spirulina
A corporate lawyer walked into a spirulina lab and stayed. At Lumen Bioscience, Brian Finrow is testing whether cheaper manufacturing can change not only how biologic drugs are made, but which problems the industry chooses to solve.
Wei-Wu He
Wei-Wu He is a scientist, inventor, entrepreneur and investor who serves as Executive Chairman and CEO of Human Longevity, Inc., the San Francisco Bay Area precision-health company that pairs whole-genome sequencing with advanced imaging and blood analytics to catch age-related disease early. Trained as a molecular biologist at Baylor College of Medicine with an MBA from Wharton, he was among the first scientists at Human Genome Sciences before building OriGene Technologies into a major research-tools business. Over three decades he has founded or funded dozens of biotech companies through his venture fund Emerging Technology Partners, and he now channels that experience into the science of extending healthy human lifespan.